Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer.

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug ...

There's nothing better than a beautiful spring day after a long, cold winter. But there's nothing worse than having that day ...

Discover the 5 most effective food allergy testing methods for children, from elimination diets to oral food challenges, ...

The treatment of asthma and allergic rhinitis using unique, humanized anti-IgE monoclonal antibodies with very particular binding specificities is now supported by the results of multiple phase II ...

Study reveals how a new IgE antibody therapy reactivates immune cells, offering a promising approach to fighting ovarian ...

An IgE antibody recognising Folate Receptor-alpha has been tested in clinical trials for ovarian cancer and preclinical studies show macrophage involvement in the anti-tumoural functions of IgE.

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.